Please login to the form below

Not currently logged in


This page shows the latest ISIS-APOCIII Rx news and features for those working in and with pharma, biotech and healthcare.

Biogen Idec gets exclusive access to Isis' neurology R&D

Biogen Idec gets exclusive access to Isis' neurology R&D

In early 2012, Biogen Idec tapped into Isis' antisense technology to try to develop a new drug called ISIS-SMN Rx to treat spinal muscular atrophy. ... Meanwhile, Isis has also just reported encouraging data from a phase II trial ISIS-APOCIII Rx for

Latest news

  • Isis rises on positive triglyceride drug data Isis rises on positive triglyceride drug data

    ISIS-APOCIII Rx can cause triglycerides to drop 75 per cent. Antisense specialist Isis Pharmaceuticals shares leapt this week after the company reported positive data with its triglyceride-lowering drug candidate. ... ISIS-APOCIII Rx achieved a

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....